207_Combined course Presentations

Trials with Cetuximab in anal cancer

Trial

N of patients

IMRT Regimen

Toxicity Efficacy

ECOG 3205 61

some 5-FU/CisP +RT + cetuximab

32% G4 5% G5 26% G4 4% G5

The 3- year LRF 23%

AMC045 HIV+

45

some NACT + 5- FU/CisP +RT + cetuximab

LRF 16%

Garg MK, et al., J Clin Oncol. 2017 Jan 9: [Epub ahead of print] Garg MK, et al., J Clin Oncol 34, 2016 (suppl; abstr 3522)